This week, we caught up with David Adams, Managing Director of the Flow Cytometry Core. Mr. Adams has served as Director of the core since 2001. He has been responsible for core facility operations and administration and has been involved in seminal development work for high-speed cell sorting instrumentation and applications at SyStemix, Inc., and BDBiosciences.
What are your thoughts on COVID-19 and adjusting to the “new normal” we are experiencing?
COVID-19 has been a challenge to everyone from those working on the front lines to those at home worrying about the next paycheck and how they are going to make rent. We are all being asked to step up in one way or another while undergoing tremendous stress. I’m not too worried about it though. People, when it comes down to it, rise to challenges. We don’t fall to them. So, we’re all doing our parts. We look for ways to help, and we persevere. We will be back together soon.
What has your core been working on in response to the pandemic?
The Flow Cytometry Core is using the time in a number of ways. We are working on additional training on such topics as advanced spectral techniques, dimensionality reduction algorithms, customer service and whatever else we find that we believe will help to improve the services offered by the core and keep our operation second to none. In addition, we are currently examining new platforms and preparing grants in order to bring additional capabilities to our research base.
What do you see for the future of your core after we all return to campus?
While standard core services will continue, there is a growing need for high-dimensional analysis and services. Spectral analyzers, for instance, can produce data on par with mass cytometry, but such work is not “plug and play”, and as we push further into high dimensional space, we will be developing and offering significant and top-tier training for our users in order to make the most of our research opportunities and resources.
What are you looking forward to most for when we get back to normal?
Honestly, I’m just looking forward to getting back into our community and working with our investigators to push research forward.